Analyses of prevention trials and intralymphatic pilot trial with the diabetes vaccine Diamyd[®] support a positive trend in genetically defined subgroups of type 1 diabetes
A combined analysis of two previous clinical prevention trials, DiAPREV-IT 1 and 2 in healthy children at high risk of type 1 diabetes, as well as additional insights from the open label pilot trial DIAGNODE-1 in children and young adults newly diagnosed with type 1 diabetes, while not reaching statistical significance, are consistent with the recently published large-scale responder analysis which showed a highly significant and clinically relevant effect of the diabetes vaccine Diamyd[®] in individuals positive for for genotypes that include HLA DR3-DQ2.HLA analysis of DiAPREV-IT 1 and 2